• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铂电阻。实验与临床现状。

Platinum resistance. Experimental and clinical status.

作者信息

Los G, Muggia F M

机构信息

University of California, UCSD Cancer Center, La Jolla.

出版信息

Hematol Oncol Clin North Am. 1994 Apr;8(2):411-29.

PMID:8040146
Abstract

It has become clear that multiple mechanisms of cellular resistance to platinum compounds exist; however, the knowledge that platinum resistance can not only be explained by processes such as reduced drug accumulation, and increased detoxification, has shifted the attention of researchers to more molecular mechanisms. The introduction of new techniques, such as the PCR technique for example, has opened the possibility to monitor genes involved in antitumor responses and may provide molecular information on the emergency of resistance.

摘要

很明显,细胞对铂类化合物存在多种耐药机制;然而,铂耐药不仅可以用药物积累减少和解毒增加等过程来解释,这一认识已将研究人员的注意力转移到更多分子机制上。新技术的引入,例如PCR技术,为监测参与抗肿瘤反应的基因提供了可能性,并可能提供有关耐药出现的分子信息。

相似文献

1
Platinum resistance. Experimental and clinical status.铂电阻。实验与临床现状。
Hematol Oncol Clin North Am. 1994 Apr;8(2):411-29.
2
Cisplatin and platinum drugs at the molecular level. (Review).顺铂及铂类药物的分子水平研究。(综述)
Oncol Rep. 2003 Nov-Dec;10(6):1663-82.
3
Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
Curr Opin Oncol. 1991 Dec;3(6):1055-9.
4
Platinum resistance: laboratory findings and clinical implications.铂电阻:实验室研究结果及临床意义。
Stem Cells. 1993 May;11(3):182-93. doi: 10.1002/stem.5530110304.
5
Role of carrier ligand in platinum resistance of human carcinoma cell lines.载体配体在人癌细胞系铂耐药中的作用。
Cancer Res. 1993 Feb 15;53(4):799-805.
6
Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.基于蒽衍生物作为载体配体的两种新型铂(II)抗癌化合物的细胞积累和DNA铂化作用
J Inorg Biochem. 2009 May;103(5):791-6. doi: 10.1016/j.jinorgbio.2009.02.005. Epub 2009 Feb 27.
7
Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.铂化合物在癌症化疗中应用的临床前研究视角
Semin Oncol. 2004 Dec;31(6 Suppl 14):1-9. doi: 10.1053/j.seminoncol.2004.11.004.
8
Clinical reversal of drug resistance in ovarian cancer.卵巢癌耐药性的临床逆转
Gynecol Oncol. 1993 Oct;51(1):90-6. doi: 10.1006/gyno.1993.1252.
9
Excision repair cross complementing-group 1: gene expression and platinum resistance.切除修复交叉互补基因1:基因表达与铂耐药性
Int J Mol Med. 2004 Dec;14(6):959-70.
10
Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.顺铂耐药机制的见解及其临床逆转潜力。
Pharmacotherapy. 1996 Jan-Feb;16(1):16-39.

引用本文的文献

1
cDNA microarray analysis of differential gene expression in gastric cancer cells sensitive and resistant to 5-fluorouracil and cisplatin.胃癌细胞对氟尿嘧啶和顺铂敏感性差异的 cDNA 微阵列分析。
Cancer Res Treat. 2005 Feb;37(1):54-62. doi: 10.4143/crt.2005.37.1.54. Epub 2005 Feb 28.
2
Identification of genes differentially expressed in association with acquired cisplatin resistance.与获得性顺铂耐药相关的差异表达基因的鉴定。
Br J Cancer. 2000 Oct;83(8):1047-54. doi: 10.1054/bjoc.2000.1420.
3
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.
聚(ADP - 核糖)聚合酶抑制剂与DNA损伤剂在卵巢肿瘤细胞系中的联合效应——特别提及顺铂
J Cancer Res Clin Oncol. 1996;122(11):665-70. doi: 10.1007/BF01209029.
4
Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.
Cancer Chemother Pharmacol. 1995;35(6):511-8. doi: 10.1007/BF00686837.
5
Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.
Cancer Chemother Pharmacol. 1995;37(1-2):150-4. doi: 10.1007/BF00685642.